MilliporeSigma, the life-sciences business of Merck KGaA, has launched Parteck MXP, a polyvinyl alcohol-based excipient for enhancing the solubility of active pharmaceutical ingredients (APIs) with poor bioavailability.

Parteck MXP excipient maintains stability at temperatures above 200 degrees Celsius and can achieve drug loads of 30% or more, according to the company. The new excipient has been tested on eight commonly used and poorly soluble APIs, including ibuprofen, indomethacin, and itraconazole, and can be used in formulations for both immediate and sustained release.

Source: Merck KGaA